Interview full of strategic steps and how we at Medicus Pharma strive to improve patient outcomes by acquiring best-in-class treatment modalities. Updates on Skinject and Antev/Teverelix. Interview from May 12, 2025. Thank you, NASDAQ for having Raza Bokhari at your studio! Watch

Medicus Pharma Ltd. announces voting results following the Annual and Special Meetings of the Shareholders. Read full press release here: Raza Bokhari newsfilecorp.com/release/259702…

$MDCX Medicus Pharma shareholders approve new board members and FDA submission for Skin Cancer therapy tinyurl.com/27e67h9b Medicus Pharma Ltd #MDCX

Dr Raza Bokhari discusses key developments following the company’s Annual and Special meetings of shareholders. Two new board members- The Honorable Cathy McMorris Rodgers, veteran public servant with more than three decades of leadership experience. Also joining the board is

Interview with Pharmaphorum is now available to watch. Medicus Pharma CEO, Dr Raza Bokhari talks about Skinject and its delivery mechanism, phase 2 study, provides updates on Antev Ltd acquisition. Raza Bokhari   More details here: pharmaphorum.com/oncology/takin…

Antev in the news following Medicus Pharma acquisition! Potential $6B market opportunity. Raza Bokhari Full story: bioxconomy.com/partnering/ant…

$MDCX on Nasdaq tower in Times Square to celebrate Antev acquisition! Raza Bokhari

$20B Skin Cancer Market Eyes Non-Surgical Solutions—Medicus Pharma Ltd Leads Innovation | Airing on CNBC What if investing in cancer care meant backing a future where treatment is non-invasive and nearly painless? Medicus Pharma (NASDAQ: MDCX) is breaking ground with a solution that

$MDCX completed a non-dilutive $8.0 million debenture financing. The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate

New interview with $MDCX CEO--Skinject expanding  its phase 2 trial beyond the shores of the United States; update on Antev acquisition and Teverelix, a next generation GnRH antagonist, focused on developing treatment of advanced prostate cancer patients with high CV risk profile

$MDCX receives FDA nod to follow 505(b)(2) regulatory pathway to develop and commercialize  D-MNA to treat BCC of the Skin. This positive feedback from a type C meeting with the FDA is a game changer with substantial time and cost savings. We are getting increasingly confident

$MDCX CEO Dr. Raza Bokhari provides update on type C FDA meeting positive feedback; FDA nod to follow 505(b)(2) regulatory pathway to commercialize D-MNA to treat BCC of the Skin presenting ~$2 billion in potential market opportunity. The outlook of $MDCX today couldn’t be more

Dr Raza Bokhari, CEO of $MDCX, to present at Family Office Summit in Dubai. Surrounding the theme “Unlocking the $1 trillion Wealth Transfer”. Dr. Bokhari, in his presentation, will highlight innovations in biotech/life sciences, the role of artificial intelligence (AI) in drug

$MDCX #CEO ⁦Raza Bokhari⁩ speaking at Family Office Summit #Dubai

Medicus Pharma Focuses on Regulatory Efficiency and Scientific Development usatoday.com/story/special/…

First UAE Patient Enrolled in Medicus' Trial for Non-Invasive BCC Therapy | Dermatology Times dermatologytimes.com/view/first-uae…

Dr. Raza Bokhari | 100 Dynamic Leaders of 2025 | Exeleon Magazine exeleonmagazine.com/dr-raza-bokhar…

Dr. Raza Bokhari | 100 Dynamic Leaders of 2025 | Exeleon Magazine exeleonmagazine.com/dr-raza-bokhar…

Medicus Pharma (MDCX) Price Target Increased by 13.56% to 22.78 | Nasdaq nasdaq.com/articles/medic…